Literature DB >> 21351860

Role of patient and public participation in health technology assessment and coverage decisions.

Devidas Menon1, Tania Stafinski.   

Abstract

Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed and 'gray' literature, and discussions with key informants to determine potential roles for patients and the public in HTA and coverage decision-making. We also summarize existing roles for both groups in jurisdictions. Although there appears to be a general view that involvement of patients and the public is highly desirable, research offering insights into the effectiveness of different approaches to accomplish this is scarce. Nonetheless, many of the HTA agencies in developed countries have established some mechanism for seeking input from patients or the public in their processes.

Entities:  

Mesh:

Year:  2011        PMID: 21351860     DOI: 10.1586/erp.10.82

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  22 in total

1.  Giving Patients a Meaningful Voice in European Health Technology Assessments: The Role of Health Preference Research.

Authors:  Axel C Mühlbacher; F Reed Johnson
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

2.  A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines.

Authors:  Josie Messina; David L Grainger
Journal:  Patient       Date:  2012       Impact factor: 3.883

Review 3.  Knowledge mobilization in the context of health technology assessment: an exploratory case study.

Authors:  Monique F Fournier
Journal:  Health Res Policy Syst       Date:  2012-04-03

4.  Transparency in reimbursement decisions: in whose best interest?

Authors:  Tania Stafinski; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

5.  Involving patients in health technology funding decisions: stakeholder perspectives on processes used in Australia.

Authors:  Edilene Lopes; Jackie Street; Drew Carter; Tracy Merlin
Journal:  Health Expect       Date:  2015-02-21       Impact factor: 3.377

6.  Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.

Authors:  Mickaël Hiligsmann; Benedict G Dellaert; Carmen D Dirksen; Verity Watson; Sandrine Bours; Stefan Goemaere; Jean-Yves Reginster; Christian Roux; Bernie McGowan; Carmel Silke; Bryan Whelan; Adolfo Diez-Perez; Elisa Torres; Georgios Papadakis; Rene Rizzoli; Cyrus Cooper; Gill Pearson; Annelies Boonen
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580

7.  Public preferences for engagement in Health Technology Assessment decision-making: protocol of a mixed methods study.

Authors:  Sally Wortley; Allison Tong; Emily Lancsar; Glenn Salkeld; Kirsten Howard
Journal:  BMC Med Inform Decis Mak       Date:  2015-07-14       Impact factor: 2.796

8.  Key concepts in consumer and community engagement: a scoping meta-review.

Authors:  Pooria Sarrami-Foroushani; Joanne Travaglia; Deborah Debono; Jeffrey Braithwaite
Journal:  BMC Health Serv Res       Date:  2014-06-13       Impact factor: 2.655

9.  Involving patient in the early stages of health technology assessment (HTA): a study protocol.

Authors:  Marie-Pierre Gagnon; Bernard Candas; Marie Desmartis; Johanne Gagnon; Daniel La Roche; Marc Rhainds; Martin Coulombe; Mylène Tantchou Dipankui; France Légaré
Journal:  BMC Health Serv Res       Date:  2014-06-20       Impact factor: 2.655

10.  Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes.

Authors:  Katharina E Fischer
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-02       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.